Literature DB >> 10819720

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha.

H Zylberberg, M L Chaix, C Bréchot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10819720     DOI： 10.7326/0003-4819-132-10-200005160-00029

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  10 in total

1.  High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain.

Authors:  Stella M Martinez; Manuel B Delgado; Javier F Castroagudín; Antonio Aguilera
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 2.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

3.  Very high prevalence of hepatitis C virus genotype 6 variants in southern Vietnam: large-scale survey based on sequence determination.

Authors:  Van H Pham; Huyen D P Nguyen; Phat T Ho; Dien V Banh; Hoa L T Pham; Phiet H Pham; Ling Lu; Kenji Abe
Journal:  Jpn J Infect Dis       Date:  2011       Impact factor: 1.362

4.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

Authors:  Jian-Qiu Han; David J Barton
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

5.  Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions.

Authors:  Suwanna Noppornpanth; Erwin Sablon; Kathy De Nys; Xuan Lien Truong; Jan Brouwer; Marianne Van Brussel; Saskia L Smits; Yong Poovorawan; Albert D M E Osterhaus; Bart L Haagmans
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

6.  Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.

Authors:  Hamad Al Ashgar; Mohammed Q Khan; Ahmed Helmy; Khalid Al Swat; Abdullah Al Shehri; Abdalla Al Kalbani; Musthafa Peedikayel; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Mohammed Al Fadda
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

7.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

8.  European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response.

Authors:  Dimitrios Dimitroulopoulos; Ioannis Elefsiniotis; Christos Pavlidis; Dimitrios Xinopoulos; Klisthenis Tsamakidis; Stamatina Patsavela; Dimitrios Kypreos; Ageliki Ferderigou; Dimitrios Korkolis; Sotirios Koutsounas; Georgios Saroglou; Emmanouil Paraskevas
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

9.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Authors:  Hamad Al Ashgar; Ahmed Helmy; Mohamed Q Khan; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Abdullah Alshehri; Abdullah Al Kalbani; Khalid Al Swat; Salim Dahab; Naser Elkum; Mohammed Al Fadda
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

10.  Distribution of Hepatitis C virus (HCV) genotypes in seropositive patients in the state of Alagoas, Brazil.

Authors:  Rosa Maria S Gonzaga; Itatiana F Rodart; Mitermayer Galvão Reis; Cícero Eduardo Ramalho Neto; Denise Wanderlei Silva
Journal:  Braz J Microbiol       Date:  2008-12-01       Impact factor: 2.476
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.